Evergold Closes $1,072,000 Private Placement to Support Follow-up Drilling at Emerging DEM1 Gold-Silver++ Discovery, BC
12 juin 2024 07h00 HE
|
Evergold Corp.
Evergold Closes $1,072,000 Private Placement to Support Follow-up Drilling at Emerging DEM1 Gold-Silver++ Discovery, BC
London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024
10 juin 2024 14h33 HE
|
London Research and Pharmaceuticals
London Research & Pharmaceuticals Presents Advancement of LRP-661, Their Lead Drug Candidate, at the New Antiepileptic Drug Conference in Madrid, Spain
ProSearch Expands Client-Focused Leadership Team Amid Continued Growth
05 juin 2024 10h00 HE
|
ProSearch
LOS ANGELES, June 05, 2024 (GLOBE NEWSWIRE) -- ProSearch, a leading provider of legal data intelligence and comprehensive discovery and compliance solutions to corporate legal departments and law...
Evergold – CSAMT Survey Over DEM1 Prospect, B.C., Reveals Large Target Extending Across All Lines and to Depth Below Reconnaissance Drill Holes
13 mai 2024 07h00 HE
|
Evergold Corp.
CSAMT Survey Over Evergold's DEM1 Prospect, B.C., Reveals Large Target Extending Across All Lines and to Depth Below Reconnaissance Drill Holes
QuisLex Incorporates ContractPodAi’s Leah Generative AI Platform into Its Workflows
30 avr. 2024 11h00 HE
|
QuisLex
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- QuisLex, a leading alternative legal services provider long recognized as a pioneer in the industry, announced today its expanded partnership with...
London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami
15 avr. 2024 08h00 HE
|
London Research and Pharmaceuticals
London Research & Pharmaceuticals Corp. Presents the Advancement of their Oral Cannabidiol Sulphate Drug Candidate at Epilepsy Therapies Conference
Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024
07 mars 2024 04h00 HE
|
Oxford BioTherapeutics
OGAP®-Verify allows for significantly enhanced sensitivity and specificity for improved target selection, dramatically accelerating drug target discoveryOGAP-Verify is now more sensitive than...
Stelmine planifie une première campagne d’exploration sur ses propriétés du nord du district de Caniapiscau
04 mars 2024 09h55 HE
|
Stelmine Canada ltée
QUÉBEC, 04 mars 2024 (GLOBE NEWSWIRE) -- Stelmine Canada (“Stelmine” ou “la Société”) (TSXV: STH ). Stelmine planifie actuellement les campagnes de travaux de la saison estivale 2024.Cette...
Stelmine is planning a maiden exploration campaign on its northern Caniapiscau properties
04 mars 2024 09h55 HE
|
Stelmine Canada Ltd.
QUÉBEC CITY, March 04, 2024 (GLOBE NEWSWIRE) -- Stelmine Canada (“Stelmine” or “the Company”) (TSXV: STH). Stelmine is currently planning its summer 2024 work program. This year, a first...
SAGA Metals Announces Intent for Uranium IPO and Provides Corporate Update
22 févr. 2024 09h00 HE
|
Saga Metals Corp.
Three projects in North America focused on the critical minerals of Uranium, Lithium, Vanadium & Titanium to support the global green energy transition.